Search Results - "Lacerda, A P"

Analysis of Serum Immunoglobulin G (IgG) Levels against Toxoplasma Gondii , Herpes Simplex Virus Types 1 and 2, Cytomegalovirus and Hepatitis C Virus in Vitiligo by Ribeiro, Rachel de Paula S, Lacerda, Kenia A P, Guillo, Lídia A

“…Pathogen infections have been associated with autoimmunity, which in turn has been implicated in the pathogenesis of vitiligo. However, the association between…”
Get full text

Leishmania ( Viannia) braziliensis is the predominant species infecting patients with American cutaneous leishmaniasis in the State of Minas Gerais, Southeast Brazil by Passos, V.M.A., Fernandes, O., Lacerda, P.A.F., Volpini, A.C., Gontijo, C.M.F., Degrave, W., Romanha, A.J.

“…Skin biopsies from 53 patients with American cutaneous leishmaniasis (ACL) from the State of Minas Gerais, Brazil, were used for a characterization of the…”
Get full text

Inheritance of lambda-cyhalothrin resistance in the predator lady beetle Eriopis connexa (Germar) (Coleoptera: Coccinellidae) by Rodrigues, Agna R.S., Torres, Jorge B., Siqueira, Herbert A.A., Lacerda, Daniel P.A.

“…[Display omitted] ► The resistance of E. connexa to lambda-cyhalothrin is autosomally inherited and incompletely dominant. ► It is estimated 54.5 generations…”
Get full text

P509 Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn’s disease by Blumenstein, I, Torres, J, Ma, C, Lindsay, J O, Ungaro, R, Thin, L, Lacerda, A P, Anyanwu, S I, Garrison, A, Ford, S, Louis, E

“…Abstract Background Upadacitinib (UPA), an oral Janus kinase inhibitor approved for the treatment of moderately to severely active Crohn’s disease (CD), has…”
Get full text

DOP47 Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatment by Panaccione, R, Melmed, G Y, Khanna, R, D’Haens, G, Danese, S, Ford, S, Anyanwu, S I, Garrison, A, Lacerda, A P, Vermeire, S

“…Abstract Background Upadacitinib (UPA), an oral Janus kinase inhibitor approved for the treatment of moderately to severely active Crohn’s disease (CD),…”
Get full text

DOP38 Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy by Colombel, J F, Hisamatsu, T, Bresso, F, Thin, L, Parra, R, Ford, S, Remple, V, Lacerda, A P, Hecht, P, Mallick, M, Garrison, A, Regueiro, M

“…Abstract Background Upadacitinib (UPA), an oral, selective JAK inhibitor demonstrated superior efficacy for clinical remission compared with placebo (PBO) and…”
Get full text

P506 Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn’s disease by baseline disease severity by Siegmund, B, Patel, K, Torres, E A, Lakatos, P L, Seidelin, J, Fleisher, M, Ford, S, Remple, V, Lacerda, A P, Anyanwu, S, Garrison, A, Panés, J

“…Abstract Background Upadacitinib (UPA) is an oral selective Janus kinase inhibitor with demonstrated efficacy in induction and maintenance treatment of Crohn’s…”
Get full text

P630 Upadacitinib Improves Clinical Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies by Schreiber, S W, Lim, A, Lacerda, A P, Allegretti, J R, Watanabe, K, Lukin, D, Dubenco, E, Ford, S, Oomen, J, Zhou, Q, Liu, J, Louis, E

“…Abstract Background Upadacitinib (UPA), an oral, selective Janus kinase inhibitor, demonstrated significantly greater efficacy compared with placebo (PBO) in…”
Get full text

P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies by Vermeire, S, Danese, S, Cohen, B L, Magro, F, Chen, Y, Ha, C, Dubcenco, E, Lacerda, A P, Marced, E, Oomen, J, Garrison, A, Peyrin-Biroulet, L

“…Abstract Background Improvement in clinical outcomes and normalisation of objective markers of inflammation, high-sensitivity C-reactive protein (hs-CRP) and…”
Get full text

OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics by Peyrin-Biroulet, L, Parkes, G, Rodríguez, C, Siffledeen, J, Wright, J, Broide, E, Ford, S, Lacerda, A P, Oomen, J, Garrison, A, Berg, S, Rubin, D T

“…Abstract Background Biologic therapies are used to treat moderate-to-severe Crohn’s Disease (CD), but many patients eventually lose response to them. With new…”
Get full text

OP10 Efficacy and safety of upadacitinib in patients with moderately to severely active Crohn’s Disease: results from the U-ENDURE long-term extension by D'Haens, G, Louis, E, Loftus Jr, E V, Regueiro, M, Jairath, V, Magro, F, Nakase, H, Dubcenco, E, Lacerda, A P, Feng, T, Duncan, B, Wang, T, Ford, S, Anyanwu, S I, Blumenstein, I

“…Abstract Background Upadacitinib (UPA) is an oral Janus kinase inhibitor approved for the treatment of moderately to severely active Crohn’s disease (CD).1 The…”
Get full text

P434 Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn’s disease: Results from induction and maintenance phase 3 trials by Ghosh, S, Feagan, B, Parra, R S, Lopes, S, Steinlauf, A, Kakuta, Y, Joshi, N, Lee, W J, Remple, V, Lacerda, A P, Zhou, Q, Xuan, S, Louis, E

“…Abstract Background Upadacitinib (UPA) demonstrated efficacy and safety in the phase 3 U-EXCEED (NCT03345836) and U-EXCEL (NCT03345849) induction, and U-ENDURE…”
Get full text

OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies by Feagan, B G, Horst, S, Dryden, G, Lindsay, J O, Ferrante, M, Dubenco, E, Lacerda, A P, Ford, S, Anyanwu, S I, Zhou, Q, Liu, J, Chen, M, Schreiber, S

“…Abstract Background Upadacitinib (UPA), an oral, reversible JAK inhibitor, demonstrated superior efficacy compared to placebo (PBO) in patients with moderate…”
Get full text

DOP40 Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib by Dubinsky, M C, D’Haens, G, Dewit, O, Juillerat, P, Panaccione, R, Fujii, T, Lacerda, A P, Dubcenco, E, Anyanwu, S, Doshi, C, Mallick, M, Garrison, A, Liu, J, Loftus Jr, E V

“…Abstract Background Corticosteroids (CS) may be used for induction of remission in Crohn’s disease (CD); however, side effects, toxicities, and low rates of…”
Get full text

P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease by Colombel, J F, Irving, P, Rieder, F, Panaccione, R, Schwartz, D, Hayashi, R, Zhu, X, Lacerda, A P, Dubcenco, E, Marced, E, Hecht, P, Feng, T, Berg, S, Reinisch, W

“…Abstract Background Intestinal and perianal fistulas and fissures are associated with significant morbidity and decreased quality of life in patients with…”
Get full text

DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study by Sandborn, W, Panés, J, Peyrin-Biroulet, L, Louis, E, Greenbloom, S, Zhou, W, Zhou, Q, Liu, J, Lacerda, A P

“…Abstract Background Patients with Crohn’s disease (CD) may lose response to treatment, requiring dose adjustments. This analysis from the CELEST study…”
Get full text

Minimal residual coronary obstructions in patients who suffered a first myocardial infarction. A prospective study comparing coronary angiography and exercise thallium scintigraphy by Macieira-Coelho, E, Cantinho, G, da Costa, B B, Garcia-Alves, M, Lacerda, A P, Dionisio, I, Carvalho, M, de Pádua, F

“…The purpose of the present study was to correlate the presence of minimal coronary obstruction (< or = 50%) assessed by coronary angiography with the presence…”
Get more information

P722 Upadacitinib was not associated with anaemia in patients with moderately to severely active ulcerative colitis: Results from the U-ACHIEVE study by D’Haens, G, Hebuterne, X, Higgins, P D R, Loftus, E V, Zhou, W, Lacerda, A P, Xie, W, Liu, J, Danese, S

“…Abstract Background Anaemia is a frequent complication in patients with Crohn’s disease and ulcerative colitis (UC), and patients who respond to treatment…”
Get full text

OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study by Sandborn, W J, Schreiber, S, Lee, S D, Lindsay, J O, Hebuterne, X, Zhou, W, Cataldi, F, Lacerda, A P, Huang, B, Xie, W, Loftus Jr, E V

“…Abstract Background The efficacy and safety of upadacitinib, an oral, selective Janus Kinase 1 inhibitor, was assessed in an 8-week Phase 2 induction study of…”
Get full text

DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study by Peyrin-Biroulet, L, Danese, S, Louis, E, Higgins, P D R, Dubinsky, M, Cataldi, F, Zhou, Q, Lee, W-J, Kligys, K, Lacerda, A P

“…Abstract Background Extra-intestinal manifestations (EIMs), such as arthropathy, are common in patients with Crohn’s disease (CD).1 The efficacy of Janus…”
Get full text